Method for predicting the sensitivity to chemotherapy

Details Method for predicting the sensitivity to chemotherapy Method for predicting the sensitivity to chemotherapy

2005-11-29

2005-11-29

Gitomer, Ralph (Department: 1651)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving transferase

C435S193000

Reexamination Certificate

active

06969592

ABSTRACT:
The present invention relates to the field of cancer treatment and, more particularly, it relates to a method for predicting the sensitivity towards chemotherapy of a patient, by measuring glutathione (GSH) blood levels of the said patient undergoing chemotherapeutic treatment.

REFERENCES:
patent: 5646177 (1997-07-01), Koch et al.
patent: 5880097 (1999-03-01), Kauvar et al.
patent: 6013462 (2000-01-01), Kauvar et al.
patent: 6576612 (2003-06-01), Fowst et al.
patent: 6756063 (2004-06-01), Kiss
patent: 0 246 868 (1987-11-01), None
patent: 0 265 719 (1988-05-01), None
patent: 0 420 121 (1991-04-01), None
patent: 2 178 036 (1987-02-01), None
patent: 0 388 948 (1990-09-01), None
patent: WO 90 11277 (1990-10-01), None
patent: WO 96 05196 (1996-02-01), None
patent: WO 97 28123 (1997-08-01), None
patent: WO 97 43258 (1997-11-01), None
patent: WO 98 04524 (1998-02-01), None
patent: WO 98 21202 (1998-05-01), None
patent: WO 99/34796 (1999-07-01), None
patent: WO 99 50265 (1999-10-01), None
patent: WO 99 50266 (1999-10-01), None
patent: WO 00 06541 (2000-02-01), None
patent: WO 00 6542 (2000-02-01), None
patent: WO 01 40181 (2001-06-01), None
patent: WO 01 85144 (2001-11-01), None
Stewart D. Non-Chemotherapeutic Agents That Potentiate Chemotherapy Efficacy. Cancer Treatment Reviews 1989, vol. 16, 1-40.
Tsuchida S. Elevation of the Placental GST in Tumor Tussies and the Levels in Sera of Patients with Cancer. Cancer Research, 49, 5225-9, 1989.
Geroni C. PNU-166196 A Novel DNA Minor Groove Binder With Enhanced Activity in Tumors Expressing High GST levels. Int J of Molecular Medicine 2001 8(Suppl 1) S10, Abstract 121.
Geroni C. PNU-166196: A Novel Antitumor Agent Whose Cytotoxicity is Enhanced in Tumor Cells with High Levels of Glutathione. Tumori Jul.-Aug., 2000. 86(4)Suppl 1, 41-42.
Gorozhanskaia E. TheRole of Glutathione and Glutathione S Transferase in Cancer Drug Resistance. Bulletin of Experimental Biology and Medicine. May 1998 125(5)562-5.
Sola F et al: “The antitumor efficacy of cytotoxic drugs is potentiated by growth-factor-complexing molecule” Cancer Chemotherapy and Pharmacology, vol. 43, No. 3, 1999, pp. 241-246, XP002104215. ISSN: 0344-5704.
Zou J P et al: “Distamycin A derivatives potentiate tumor-necrosis factor activity via the modulation of tyrosine phosphorylation” International Journal fo cance, New York, NY, US, vol. 72, No. 5, 1997, pp. 810-814, XP002104217 ISSN: 0020-7136.
Tagliabue G et al: “Combination of the New Minor Groove Alkylator Tallimustine and Melphalan” European Journal of Cancer, Pergamon Press, Oxford, GB, vol. 33, No. 2, (Feb. 1997), pp. 284-287, XP004282511 ISSN: 0959-8049.
Geroni Cristina et al: “Antitumor activity of PNU-166196, a novel DNA minor groove binder selected for clinical development.” Proceedings of the American Association for Cancer Research Annual, No. 41, (Mar. 2000), pp. 425-426, XP001039861 91 st Annual Meeting of the American Association for Cancer Research.; San 2000, Mar. 2000 ISSN: 0197-016X, abstract only.
Baradi, Pier Giovanni et al: “Synthesis and antitumor activity of novel distamycin derivatives”Bioorg. Med. Chem. Lett. (1996), 6(11), 1241-1246 XP004134862 p. 1241, paragraph 2 example SCHEME1 p. 1244, paragraph 1 table 1 page 1244, paragraph 4 -p. 1245, paragraph 1.
Cozzi P et al: XP004200573 “Cytotoxic alpha-Bromoacrylic Derivatives of Distamycin Analogues Modified at the Amidino Moiety” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 10, No. 11, (Jun. 2000), pp. 1273-1276, ISSN: 0960-894X.
Cozzi P et al: XP004200572 “Cytotoxic Halogenoacrylic Derivatives of Distamycin A” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 10, No. 11, (Jun. 2000), pp. 1269-1272, ISSN: 0960-894 X.
Catharina J A Van Moorsel et al: XP002110339 “Gemcitabine: Futrue Prospects of Single-Agent and Combination Studies” Oncologist, Alphamed Press, US, vol. 2, No. 3, 1997, pp. 127-124, ISSN: 1083-7159.
Budavari S (ED): XP002191966 “The Merck Index (12th Edition)” Merck Index, Encyclopedia of Chemicals, Drugs, and Biologicals, 13th. Edition 1996, Whitehouse Station, Merck & Co, US, vol. ED. 13, 2001, p. 4206 ISBN: 0-911910-12-3.
Mosconi A M et al: XP004282426 “Combination Therapy with Gemcitabine in Non-small Cell Lung Cancer” European Journal of Cancer, Pergamon Press, Oxford, GB, vol. 33, (Jan. 1997), pp. S14-S17, ISSN: 0959-8049.
D'Alessio, Roberto et al: “Structure-activity relationship of novel distamycin A derivatives: Synthesis and antitumor activity” Bioorg. Med. Chem. Lett. (1994), 4(12), 1467-72, XP000671766.
Stewart D J et al: “Non-Chemotherapeutic Agents that Potentiate Chemotherapy Efficacy” Cancer Treatment Reviews, vol. 16, No. 1, 1989, pp. 1-40, XP001039737 ISSN: 0305-7372 p. 18, paragraph 3 -p. 19, paragraph 1.
Colella, G. et al: “Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents” BR. J. Cancer (1999), 80(3/4), 338-343, XP001039733.
Giustianna Maria et al: “In vivo induction of apoptosis with PNU-166196 in human ovarian carcinoma xenografts.” Proceedings of the American Association for Cancer Research Annual, No. 41, (Mar. 2000), p. 825 XP001039865 91st Annual Meeting of the American Association for Cancer Research.: San Francisco, California, USA; Apr. 1-5, 2000, Mar., 2000 ISSN: 0197-016x, abstract.
Tsuchida S et al: “Elevation of the Placental Glutathione-S-Transferase Form GST-Pl in Tumor Tissues and the Levels in Sera of Patients with Cancer” Cancer Research, vol. 49, No. 18, 1989, pp. 5225-5229, XP001039783 ISSN: 0008-5472 abstract p. 5225, column 1, paragraph 1 p. 5228, column 1, paragraph 1 p. 5228, column 2, paragraph 2.
Cozzi P: “A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers.” FARMACO, (Jan.-Feb. 2001) 56 (1-2) 57-65., XP001039805 abstract p. 58, column 2, paragraph 4 p. 59, column 1, paragraph 1 figure 5 p. 60, column 1, paragraph 2 -p. 61, column 1, paragraph 4 tables 2,3 p. 62, column 2, paragraph 3 figures 9, 10 table 5 p. 63, column 1, paragraph 1 -column 2, paragraph 2.
Baraldi, Pier Giovanni et al: “Synthesis and Antitumor Activity of New Benzoheterocyclic Derivatives of Distamycin A” J. Med. Chem. (2000), 43(14), 2675-2684 , (Jul. 13, 2000), XP001039581 abstract p. 2676, column 1; tables p. 2676, column 1, paragraph 1 tables 1,2 p. 2678, column 2, paragraph 5 -p. 2679, column 1, paragraph 1 p. 2680, column 2, paragraph 3.
Boger et al., “Total Synthesis of Distamycin A and 2640 Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New Bioactive DNA Binding Agents and Development of a Rapid, High-Trroughput Screen for Determining Realtive DNA Binding Affinity or DNA Binding Sequence Selectivity”, J. Am. Chem. Soc. 2000, 122, 6382-6394.

Affiliated with

Also associated with

Rating

Method for predicting the sensitivity to chemotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for predicting the sensitivity to chemotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for predicting the sensitivity to chemotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3484827